U.K. government has ordered another 1.75 million courses of oral molnupiravir COVID-19 treatment from Merck & Co. and Ridgeback Biotherapeutics. Previously, the U.K. purchased 480,000 courses of the drug. Merck & Co. already has pre-delivery agreements for molnupiravir with the governments of more than 30 countries.